IvaBRAdine blocK of Funny Current for Heart Rate Control in permanEnt Atrial Fibrillation. (BRAKE-AF Study).

Atrial Fibrillation Clinical Trial

— BRAKE-AF  

Official title:

A Phase III Clinical Trial to Compare Ivabradine Versus Digoxin in the Heart Rate Control in Patients With Permanent Atrial Fibrillation Under Treatment With Beta-blockers or Calcium Antagonists.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03718273
• Other study ID #: BRAKE-AF
• Secondary ID: 2018-001936-23
• Status: Completed
• Phase: Phase 3
• Start date: October 19, 2018
• Est. completion date: June 30, 2022

Study information

• Verified date: October 2022
• Source: Hospital Universitario 12 de Octubre
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The BRAKE-AF Study is a phase III, randomised, controlled, multicentric, open-label clinical trial to prove the noninferiority of ivabradine versus digoxin in the treatment of permanent atrial fibrillation. The total duration of the study is 3 years, with 24 months of enrolment, treatment and follow-up.

Description:

This is a non-commercial, investigator-driven clinical study funded through a public competitive call by Instituto de Salud Carlos III, Spanish Ministry of Economy (PI17/01272).

The study is coordinated by the main investigator from Hospital Universitario 12 de Octubre in Madrid; the sponsorship is performed by Dr. Adolfo Fontenla (Hospital Universitario 12 de Octubre). Several responsibilities are delegated to the Clinical Research Unit (Hospital 12 de Octubre, Madrid, Spain).

The study was planned according to the Good Clinical Practices. BRAKE-AF Study has been approved by the Ethics Committee and Spanish Health Authorities. All participating patients must give written informed consent before any study procedure occur.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 68
• Est. completion date: June 30, 2022
• Est. primary completion date: February 22, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Age = 18 years.

2. Permanent Atrial Fibrillation (AF) at the time of randomization, with no prospect of cardioversion, antiarrhythmic treatment with group I or III drugs, or pulmonary vein ablation.

3. Symptoms attributable to AF associated with the presence of at least one of the following inadequate Heart rate (HR) control criteria:

1. HR at rest > 110 bpm (on ECG -electrocardiogram- performed in the 14 days prior to inclusion).

2. HR at rest between 80 and 110 bpm (on ECG performed in the 14 days prior to inclusion) and at least one of the following criteria:

i. HR in exercise of moderate intensity > 130 bpm (measured in an ergometry or in a Holter-ECG performed in the 60 days prior to inclusion).

ii. Average daytime HR > 80 bpm (measured on a Holter-ECG performed in the 60 days prior to inclusion).

4. Be receiving treatment with beta-blockers or non-dihydropyridine calcium channel blockers (verapamil or diltiazem) at the maximum dose recommended or tolerated by the patient.

5. Be able to voluntarily give their informed consent.

6. B|ood test carried out in the 6 months prior to inclusion' including: blood count, thyroid hormones and creatinine, in order to rule out secondary causes of poor HR control. The creatinine figure will be used to calculate the creatinine clearance in order to adjust the dose of patients who are randomized to the Digoxin group.

7. Transthoracic echocardiogram to rule out, eg, severe valvular heart disease, hypertrophic cardiomyopathy. The one performed in the year prior to inclusion in the study will be considered acceptable provided that the patient's clinical situation has been stable in that period of time.

Exclusion Criteria:

1. Previous treatment or patients with a known contraindication to Ivabradine or Digoxin or to any excipient of both drugs.

2. Paroxysmal or intermittent complete atrioventricular (AV) block in patients not carrying a pacemaker.

3. Decompensated heart failure requiring inotropic and I or intravenous diuretics in the week prior to randomization or in New York Heart Association (NYHA) functional class IV or on the cardiac transplant waiting list,

4. Acute pericarditis, acute myocarditis or constrictive pericarditis.

5. Obstructive hypertrophic cardiomyopathy.

6. Valvular disease requiring surgical or percutaneous correction.

7. Medical causes that justify poor control of heart rate: fever' anemia, hyperthyroidism, pheochromocytoma' etc.

8. Severe hypotension (blood pressure <90/50 mmHg).

9. Concomitant treatment with potent cytochrome P450 3A4 inhibitors such as azole antifungals (ketoconazole, itraconazole), macrolide antibiotics (clarithromycin, oral erythromycin, josamycin, telithromycin) HIV protease inhibitors (nelfinavir, ritonavir) and nefazodone.

10. Severe renal insufficiency (CrCl <30 ml/Kg/min) or in a hemodialysis program.

11. Severe hepatic insufficiency.

12. Major surgery (including cardiac surgery) in the month prior to randomization.

13. Severe concomitant illness that supposes a llfe expectancy of less than one year.

14. Impossibility of carrying out scheduled visits to the protocol.

15. Woman of childbearing age (under 50 years of age, except for those who present a gynecological report that proves the presence of menopause) and women who are breastfeeding.

16. Participation in a clinical trial in the previous 6 months.

17. Patients with acute myocardial infarction or unstable angina.

18. Patient with a recent stroke.

19. Patients with congenital long QT syndrome or treated with drugs that prolong this interval.

Related Conditions & MeSH terms

• Atrial Fibrillation
• Heart Diseases

Intervention

Drug:
• Ivabradine
Ivabradine 5 mg, twice a day the first month administered by mouth. If the tolerance is good, the dose will be increased to 7.5 mg on month 2 and will continue until the third month. Patients with 75 or more years of age will receive an initial dose of 2.5 mg / twice a day, which can be increased to 5 mg / twice a day in week 7 and to 7.5 mg in month 1 if the tolerance has been good
• Digoxin
The initial dose will be based on whether there are factors such as age over 80 years, weight less than 60 kg and creatinine clearance <60ml / min, if there is no factor, the oral dose will be 0.25mg / 24h. If there are 2 factors, the dose will be 0.15 mg / 24 h. and if there are 2 or 3 factors, the dose will be 0.10 mg / 24 h.

Locations

Country	Name	City	State
Spain	Hospital Universitario de Burgos	Burgos
Spain	Fundación Jiménez Díaz	Madrid
Spain	Hospital Clínico San Carlos	Madrid
Spain	Hospital Universitario 12 de Octubre	Madrid
Spain	Hospital Universitario de Getafe	Madrid
Spain	Hospital Universitario La Paz	Madrid
Spain	Hospital Universitario Puerta de Hierro	Madrid
Spain	Hospital Universitario Ramón y Cajal	Madrid
Spain	Hospital Universitario Rey Juan Carlos	Madrid
Spain	Hospital Virgen de la Salud	Toledo

Sponsors (3)

Lead Sponsor	Collaborator
Adolfo Fontenla	Carlos III Health Institute, Spanish Clinical Research Networt (SCReN)

Country where clinical trial is conducted

Spain, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Heart rate reduction.	Reduction of the mean daytime heart rate registered in Holter- electrocardiogram (ECG) after treatment with Ivabradine or Digoxin.	3 months
Primary	Serious adverse events	Proportion of patients experiencing syncope, severe bradycardia or any serious adverse reaction requiring hospitalization, emergency visit or death of the patient during treatment with Ivabradine or Digoxin.	3 months
Secondary	Reduction in the scale of atrial fibrillation (AF) symptoms according to the European Hearth Rhythm Association (EHRA) Score modified.	Percentage of patients who experience a reduction in the scale of atrial fibrillation. symptoms according to the EHRA Score modified.	Months 1 and 3.
Secondary	6 minute walk test (6MWT).	Increase in meters in the 6MWT.	Baseline and after 3 months.
Secondary	Quality-of-Life Short Form 36 (SF-36) Health Survey (QoL SF-36) Score.	Increase in the score obtained in global quality of life parameters analyzed by the SF-36 questionnaire.	At baseline and 3 months.
Secondary	The Atrial Fibrillation Effect on Quality-of-Life (QoL AFEQT) score.	Increase in the score obtained in parameters of quality of life quality of life associated with AF analyzed by the AFEQT questionnaire.	At baseline and 3 months
Secondary	Reduction of the daytime Health rate.	Reduction of the average daytime Heart Rate (HR) recorded in Holter-ECG	1 month
Secondary	Reduction of resting Health Rate.	Reduction of resting heart rate (HR) recorded on one electrocardiogram (ECG).	1 and 3 months
Secondary	Reduction of the maximum heart rate (HR) recorded.	Reduction of the maximum HR recorded in Holter-ECG	1 and 3 months
Secondary	Reduction of the mean HR recorded.	Reduction of the mean HR in 24 hours recorded in Holter-ECG .	1 and 3 months
Secondary	Reduction of the HR delta.	Reduction of the HR delta (difference between maximum HR and mean HR in 24 hours) recorded in Holter-ECG.	1 and 3 months
Secondary	Reduction of HR in moderate exercise.	Reduction of HR in moderate exercise (maximum HR measured by Holter-ECG during the 6-minute walk test.	3 months
Secondary	Percentage of patients with non-severe bradycardia.	Percentage of patients who experience non-severe bradycardia during the study treatment.	1 and 3 months
Secondary	Percentage of patients who experience any adverse reaction.	Percentage of patients who experience any adverse reaction to the study drugs.	1 and 3 months
Secondary	Percentage of patients who voluntarily abandon the study drugs.	Percentage of patients who voluntarily abandon the study drugs.	3 months
Secondary	Proportion of hospitalizations, emergency visits and mortality due to a major cardiovascular event.	Proportion of patients experiencing hospitalizations, emergency visits and mortality due to a major cardiovascular event during treatment with the study drug.	3 months